GAL and liver cancer: Annexin V-FITC/PI double staining and TUNEL assays quantitatively and qualitatively indicated that RGPPNs prepared with the new synthetic Gal-SP188–PLGA had better active targeting functions and a stronger inhibitory effect on liver cancer cells with high ASGPR expression.